Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:
EQT Life Sciences’ BioCapital Europe
Amsterdam, The Netherlands, March 9, 2023
Erik Manting, CEO of Mendus, will attend the conference.
BIO-Europe Spring 2023
Basel, Switzerland, March 20–22, 2023
Members of Mendus’ leadership team will participate.
8th Annual Innate Killer Summit 2023
San Diego, CA, USA, March 27–30, 2023
Erik Manting, CEO of Mendus, will give a presentation and update on Mendus’ novel method for the expansion of memory NK cells.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
Telephone: +49 160 9352 9951
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/